

**Referências:** 1. Califano JA et al. Em: Amin MB et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017:171-181. 2. Karia PS et al. J Am Acad Dermatol. 2013;68(6):957-966. 3. Cancer stat facts: melanoma of the skin. Surveillance, Epidemiology, and End Results Program website. <https://seer.cancer.gov/statfacts/html/melan.html>. Acedido a 5 dezembro 2018. 4. Watson M et al. MMWR Morb Mortal Wkly Rep. 2015;64(47): 1312-1314. 5. Resumo das Características do Medicamento LIBTAYO (cemiplimab) 6. Migden, Michael R., et al. "PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma." New England Journal of Medicine 379.4 (2018): 341-351 ; 7. Chang, Anne Lynn S., et al. "Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial." (2020): 294- 305